Nanjing Vishee Medical Technology Co., Ltd
Sümbol: 688580.SS
SHH
47.44
CNYTuruhind täna
25.8198
P/E suhe
0.0000
PEG suhe
3.23B
MRK Cap
- 0.01%
DIV tootlus
Nanjing Vishee Medical Technology Co., Ltd (688580-SS) Finantsaruanded
Bilanss
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1155 | 1248.1 | 1366 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 2266.4 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0 | 47.3 | 31.9 | 36.7 | ||||||||||
balance-sheet.row.inventory | 0 | 39.9 | 34.8 | 30.4 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 12.6 | 4.3 | 1.2 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 1254.8 | 1319.2 | 1434.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 321.5 | 172.5 | 100.3 | ||||||||||
balance-sheet.row.goodwill | 0 | 69.3 | 69.3 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 120.6 | 106.5 | 18.8 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 189.9 | 175.8 | 18.8 | ||||||||||
balance-sheet.row.long-term-investments | 0 | -2244.3 | 0 | 0.8 | ||||||||||
balance-sheet.row.tax-assets | 0 | 15.1 | 7.9 | 12.7 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2269 | 8.8 | 71.9 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 551.2 | 365 | 204.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.account-payables | 0 | 18 | 19.7 | 9.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 1.2 | 1.2 | ||||||||||
balance-sheet.row.tax-payables | 0 | 19.6 | 21.1 | 29.3 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 1.8 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 133.7 | 94.8 | 1.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 27.6 | 26.4 | 1.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 1.2 | 1.8 | ||||||||||
balance-sheet.row.total-liab | 0 | 179.3 | 155.7 | 105.7 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 68.6 | 68.6 | 68.3 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 438.4 | 349.1 | 344.3 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1588.9 | 34.8 | 58.1 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -469.2 | 1076 | 1062.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 22 | 0 | 0.8 | ||||||||||
balance-sheet.row.total-debt | 0 | 0 | 1.2 | 3 | ||||||||||
balance-sheet.row.net-debt | 0 | -1155 | -1246.9 | -1363 |
Rahavoogude aruanne
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 93.8 | 177.5 | 143.1 | |||||||||
cash-flows.row.depreciation-and-amortization | 0 | 17.1 | 11.1 | 8.8 | |||||||||
cash-flows.row.deferred-income-tax | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.stock-based-compensation | 0 | -2.8 | 21.4 | 1.1 | |||||||||
cash-flows.row.change-in-working-capital | 0 | -8.7 | -33.5 | -19.1 | |||||||||
cash-flows.row.account-receivables | 0 | 7.3 | -13.1 | -15.9 | |||||||||
cash-flows.row.inventory | 0 | 1.8 | 6.7 | -5.6 | |||||||||
cash-flows.row.account-payables | 0 | -20.1 | -19 | 3.4 | |||||||||
cash-flows.row.other-working-capital | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.other-non-cash-items | 0 | -15.6 | -11 | -12.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.acquisitions-net | 0 | -34.2 | 0 | 11.7 | |||||||||
cash-flows.row.purchases-of-investments | 0 | -3648 | -4264 | -2102.4 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 3664 | 4284.6 | 2115.8 | |||||||||
cash-flows.row.other-investing-activites | 0 | 9 | -10 | -11.7 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -104.8 | -76.8 | 1.9 | |||||||||
cash-flows.row.debt-repayment | 0 | -2 | -1.3 | -14 | |||||||||
cash-flows.row.common-stock-issued | 0 | 16.9 | -0.3 | -18 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | -14.9 | 1.6 | 18 | |||||||||
cash-flows.row.dividends-paid | 0 | -88.9 | -71.8 | -50.3 | |||||||||
cash-flows.row.other-financing-activites | 0 | -6.1 | -9.2 | 1059.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -95 | -81 | 994.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 0 | -113.6 | -0.4 | 1117.4 | |||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1247.7 | 1361.3 | 1361.7 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1361.3 | 1361.7 | 244.4 | |||||||||
cash-flows.row.operating-cash-flow | 0 | 86.2 | 157.4 | 120.8 | |||||||||
cash-flows.row.capital-expenditure | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.free-cash-flow | 0 | -9.4 | 70 | 109.1 |
Kasumiaruande rida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 462.2 | 321.6 | 430 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 130.5 | 88.5 | 108.5 | ||||||||||
income-statement-row.row.gross-profit | 0 | 331.7 | 233.1 | 321.6 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 208.7 | 162.9 | 163.1 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 339.2 | 251.4 | 271.6 | ||||||||||
income-statement-row.row.interest-income | 0 | 19.3 | 19.3 | 16.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 20.1 | 19.5 | 14.9 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 148.4 | 104.5 | 194.7 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 150 | 105.8 | 197.4 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 13.8 | 12 | 19.8 | ||||||||||
income-statement-row.row.net-income | 0 | 136.3 | 93.8 | 177.8 |
Korduma kippuv küsimus
Mis on Nanjing Vishee Medical Technology Co., Ltd (688580.SS) koguvara?
Nanjing Vishee Medical Technology Co., Ltd (688580.SS) koguvara on 1806024041.000.
Mis on ettevõtte aastane tulu?
Aastane tulu on N/A.
Mis on ettevõtte kasumimarginaal?
Ettevõtte kasumimarginaal on 0.715.
Mis on ettevõtte vaba rahavoog?
Vaba rahavoog on -0.334.
Mis on ettevõtte puhaskasumimarginaal?
Puhaskasumimarginaal on 0.282.
Mis on ettevõtte kogutulu?
Kogutulu on 0.306.
Mis on Nanjing Vishee Medical Technology Co., Ltd (688580.SS) puhaskasum (puhaskasum)?
Puhaskasum (netotulu) on 136258629.000.
Kui suur on ettevõtte koguvõlg?
Koguvõlg on 0.000.
Mis on tegevuskulude arv?
Tegevuskulud on 208672734.000.
Milline on ettevõtte rahaline näitaja?
Ettevõtte raha on 0.000.